帕金森病伴发神经精神症状的临床和治疗进展

doi:10.3969/j.issn.1003-9198.2024.10.004

摘要/Abstract

摘要： 神经精神症状(neuropsychiatric symptoms,NPS)如情感障碍、精神病、行为改变和认知功能障碍在PD中很常见,然而其并没有得到充分的认识和治疗,常常导致病人预后不良。NPS的流行病学、临床表现、神经基础和管理策略并未得到完全了解。心理和社会因素以及多巴胺能药物暴露与某些症状发生之间存在关联,表明NPS具有神经生物学基础。目前临床上已经研究了一系列精神药物、心理治疗技术、刺激疗法和其他非药物疗法,这些疗法的应用被证实有利于PD病人的NPS管理。NPS的适当管理包括从识别其在整个疾病过程中的表现和时间,到采用多学科方法的不同治疗策略(即药物和非药物)的结合,对于PD的全面护理和治疗至关重要。

关键词: 神经精神症状, 帕金森病, 抑郁, 焦虑, 淡漠, 认知障碍, 冲动控制障碍

中图分类号:

蔡增林, 李敬伟. 帕金森病伴发神经精神症状的临床和治疗进展[J]. 实用老年医学, 2024, 38(10): 983-989.

参考文献

[1] CHAUDHURI K R, SAUERBIER A, ROJO J M, et al.The burden of non-motor symptoms in Parkinson’s disease using a self-completed non-motor questionnaire: a simple grading system[J]. Parkinsonism Relat Disord,2015, 21(3):287-291.
[2] CHAUDHURI K R, ODIN P, ANTONINI A,et al.Parkinson’s disease: the non-motor issues[J]. Parkinsonism Relat Disord, 2011, 17(10):717-723.
[3] DUNLOP B W, NEMEROFF C B.The role of dopamine in the pathophysiology of depression[J]. Arch Gen Psychiatry,2007, 64(3):327-337.
[4] HEINZEL S, BERG D, GASSER T, et al.Update of the MDS research criteria for prodromal Parkinson’s disease[J]. Mov Disord, 2019, 34(10):1464-1470.
[5] MACÍAS-GARCÍA P, RASHID-LÓPEZ R, CRUZ-GÓMEZ Á J, et al.Neuropsychiatric symptoms in clinically defined Parkinson’s disease: an updated review of literature[J]. Behav Neurol, 2022, 2022:1213393.
[6] WEINTRAUB D, MOBERG P J, DUDA J E, et al.Recognition and treatment of depression in Parkinson’s disease[J]. J Geriatr Psychiatry Neurol,2003, 16(3):178-183.
[7] CARDOSO E F, MAIA F M, FREGNI F, et al.Depression in Parkinson’s disease: convergence from voxel-based morphometry and functional magnetic resonance imaging in the limbic thalamus[J]. Neuroimage, 2009, 47(2):467-472.
[8] HEMMERLE A M, HERMAN J P, SEROOGY K B.Stress, depression and Parkinson’s disease[J]. Exp Neurol,2012, 233(1):79-86.
[9] CHAUDHURI K R, SCHAPIRA A H.Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment[J]. Lancet Neurol, 2009, 8(5):464-474.
[10] HONG C T, TAN S, HUANG T W.Psychotherapy for the treatment of anxiety and depression in patients with Parkinson disease: a meta-analysis of randomized controlled trials[J]. J Am Med Dir Assoc,2021, 22(11):2289-2295.e2.
[11] SEPPI K, RAY CHAUDHURI K, COELHO M, et al.Update on treatments for nonmotor symptoms of Parkinson’s disease—an evidence-based medicine review[J]. Mov Disord, 2019, 34(2):180-198.
[12] LI S, JIAO R, ZHOU X, et al.Motor recovery and antidepressant effects of repetitive transcranial magnetic stimulation on Parkinson disease: a PRISMA-compliant meta-analysis[J]. Medicine: Baltimore, 2020, 99(18):e19642.
[13] WILLIAMS N R, BENTZLEY B S, SAHLEM G L, et al.Unilateral ultra-brief pulse electroconvulsive therapy for depression in Parkinson’s disease[J]. Acta Neurol Scand,2017, 135(4):407-411.
[14] ZHANG Q, HU J, WEI L, et al.Effects of dance therapy on cognitive and mood symptoms in people with Parkinson’s disease: a systematic review and meta-analysis[J]. Complement Ther Clin Pract, 2019, 36:12-17.
[15] RUTTEN S, VRIEND C, SMIT J H, et al.Bright light therapy for depression in Parkinson disease: a randomized controlled trial[J]. Neurology, 2019, 92(11):e1145-e1156.
[16] SMITH K M, EYAL E, WEINTRAUB D.Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability[J]. JAMA Neurol, 2015, 72(1):88-95.
[17] MURDOCH K C, LARSEN D, EDEY W, et al.The efficacy of the Strength, Hope and Resourcefulness Program for people with Parkinson’s disease (SHARP-PWP): a mixed methods study[J]. Parkinsonism Relat Disord, 2020, 70:7-12.
[18] RAY CHAUDHURI K, LETA V, BANNISTER K, et al.The noradrenergic subtype of Parkinson disease: from animal models to clinical practice[J]. Nat Rev Neurol,2023, 19(6):333-345.
[19] DISSANAYAKA N N, SELLBACH A, MATHESON S, et al.Anxiety disorders in Parkinson’s disease: prevalence and risk factors[J]. Mov Disord, 2010, 25(7):838-845.
[20] DISSANAYAKA N N, FORBES E J, PEREPEZKO K, et al.Phenomenology of atypical anxiety disorders in Parkinson’s disease: a systematic review[J]. Am J Geriatr Psychiatry, 2022, 30(9):1026-1050.
[21] SCHNEIDER R B, AUINGER P, TAROLLI C G, et al.A trial of buspirone for anxiety in Parkinson’s disease: safety and tolerability[J]. Parkinsonism Relat Disord,2020, 81:69-74.
[22] MOONEN A J H, MULDERS A E P, DEFEBVRE L, et al.Cognitive behavioral therapy for anxiety in Parkinson’s disease: a randomized controlled trial[J]. Mov Disord,2021, 36(11):2539-2548.
[23] WEINTRAUB D, AARSLAND D, BIUNDO R, et al.Management of psychiatric and cognitive complications in Parkinson’s disease[J]. BMJ, 2022, 379:e068718.
[24] BAN M, YUE X, DOU P, et al.The effects of yoga on patients with Parkinson’s disease: a meta-analysis of randomized controlled trials[J]. Behav Neurol,2021, 2021:5582488.
[25] STARKSTEIN S E, MERELLO M, JORGE R, et al.The syndromal validity and nosological position of apathy in Parkinson’s disease[J]. Mov Disord,2009, 24(8):1211-1216.
[26] ISELLA V, MELZI P, GRIMALDI M, et al.Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson’s disease[J]. Mov Disord,2002, 17(2):366-371.
[27] REIJNDERS J S, SCHOLTISSEN B, WEBER W E, et al.Neuroanatomical correlates of apathy in Parkinson’s disease: a magnetic resonance imaging study using voxel-based morphometry[J]. Mov Disord, 2010, 25(14):2318-2325.
[28] MAILLET A, MÉTÉREAU E, TREMBLAY L, et al.Serotonergic and dopaminergic lesions underlying parkinsonian neuropsychiatric signs[J]. Mov Disord,2021, 36(12):2888-2900.
[29] HAUSER R A, SLAWEK J, BARONE P, et al.Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson’s disease[J]. BMC Neurol, 2016, 16:90.
[30] TAKAHASHI M, TABU H, OZAKI A, et al.Antidepressants for depression, apathy, and gait instability in Parkinson’s disease: a multicenter randomized study[J]. Intern Med, 2019, 58(3):361-368.
[31] MELE B, VAN S, HOLROYD-LEDUC J, et al.Diagnosis, treatment and management of apathy in Parkinson’s disease: a scoping review[J]. BMJ Open, 2020, 10(9):e037632.
[32] MONTAGNESE M, VIGNANDO M, FFYTCHE D, et al.Cognitive and visual processing performance in Parkinson’s disease patients with vs without visual hallucinations: a meta-analysis[J]. Cortex, 2022, 146:161-172.
[33] FORSAA E B, LARSEN J P, WENTZEL-LARSEN T, et al.A 12-year population-based study of psychosis in Parkinson disease[J]. Arch Neurol,2010, 67(8):996-1001.
[34] WOLTERS E C.Intrinsic and extrinsic psychosis in Parkinson’s disease[J]. J Neurol, 2001, 248(Suppl 3):III22-III27.
[35] VIGNANDO M, FFYTCHE D, LEWIS S J G, et al.Mapping brain structural differences and neuroreceptor correlates in Parkinson’s disease visual hallucinations[J]. Nat Commun, 2022, 13(1):519.
[36] ZHANG S, MA Y.Emerging role of psychosis in Parkinson’s disease: from clinical relevance to molecular mechanisms[J]. World J Psychiatry, 2022, 12(9):1127-1140.
[37] KITTEN A K, HALLOWELL S A, SAKLAD S R, et al.Pimavanserin: a novel drug approved to treat Parkinson’s disease psychosis[J]. Innov Clin Neurosci, 2018, 15(1/2):16-22.
[38] TAMPI R R, TAMPI D J, YOUNG J J, et al.Evidence for using pimavanserin for the treatment of Parkinson’s disease psychosis[J]. World J Psychiatry, 2019, 9(3):47-54.
[39] ELDER G J, COLLOBY S J, FIRBANK M J, et al.Consecutive sessions of transcranial direct current stimulation do not remediate visual hallucinations in Lewy body dementia: a randomised controlled trial[J]. Alzheimers Res Ther, 2019, 11(1):9.
[40] OLANOW C W, STERN M B, SETHI K.The scientific and clinical basis for the treatment of Parkinson disease (2009)[J]. Neurology, 2009, 72(21 Suppl 4):S1-S136.
[41] WEINTRAUB D, KOESTER J, POTENZA M N, et al.Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients[J]. Arch Neurol, 2010, 67(5):589-595.
[42] ANTONINI A, BARONE P, BONUCCELLI U, et al.ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson’s disease[J]. J Neurol Neurosurg Psychiatry, 2017, 88(4):317-324.
[43] CORVOL J C, ARTAUD F, CORMIER-DEQUAIRE F, et al.Longitudinal analysis of impulse control disorders in Parkinson disease[J]. Neurology, 2018, 91(3):e189-e201.
[44] SMITH K M, XIE S X, WEINTRAUB D.Incident impulse control disorder symptoms and dopamine transporter imaging in Parkinson disease[J]. J Neurol Neurosurg Psychiatry, 2016, 87(8):864-870.
[45] YU X X, FERNANDEZ H H.Dopamine agonist withdrawal syndrome: a comprehensive review[J]. J Neurol Sci, 2017, 374:53-55.
[46] PAPAY K, XIE S X, STERN M, et al.Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study[J]. Neurology, 2014, 83(9):826-833.
[47] LIANG J W, SHANKER V L, GROVES M.Naltrexone for impulse control disorders in Parkinson disease: a placebo-controlled study[J]. Neurology, 2015, 84(13):1386-1387.
[48] ZHANG X L, WANG G B, ZHAO L Y, et al.Clonidine improved laboratory-measured decision-making performance in abstinent heroin addicts[J]. PLoS One, 2012, 7(1):e29084.
[49] LAURENCIN C, TIMESTIT N, MARQUES A, et al.Efficacy and safety of clonidine for the treatment of impulse control disorder in Parkinson’s disease: a multicenter, parallel, randomised, double-blind, Phase 2b Clinical trial[J]. J Neurol, 2023, 270(10):4851-4859.
[50] KEHAGIA A A, HOUSDEN C R, REGENTHAL R, et al.Targeting impulsivity in Parkinson’s disease using atomoxetine[J]. Brain, 2014, 137(Pt 7):1986-1997.
[51] BORCHERT R J, RITTMAN T, PASSAMONTI L, et al.Atomoxetine enhances connectivity of prefrontal networks in Parkinson’s disease[J]. Neuropsychopharmacology, 2016, 41(8):2171-2177.
[52] AVERBECK B B, O’SULLIVAN S S, DJAMSHIDIAN A.Impulsive and compulsive behaviors in Parkinson’s disease[J]. Annu Rev Clin Psychol, 2014, 10:553-580.
[53] OKAI D, ASKEY-JONES S, SAMUEL M, et al.Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers[J]. Neurology, 2013, 80(9):792-799.
[54] BIUNDO R, WEIS L, ANTONINI A.Cognitive decline in Parkinson’s disease: the complex picture[J]. NPJ Parkinsons Dis, 2016, 2:16018.
[55] GONZÁLEZ-USIGLI H A, ORTIZ G G, CHARLES-NIO C, et al.Neurocognitive psychiatric and neuropsychological alterations in Parkinson’s disease: a basic and clinical approach[J]. Brain Sci, 2023, 13(3):508.
[56] ROLINSKI M, FOX C, MAIDMENT I, et al.Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease[J]. Cochrane Database Syst Rev, 2012, 2012(3):CD006504.
[57] WANG H F, YU J T, TANG S W, et al.Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson’s disease, Parkinson’s disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis[J]. J Neurol Neurosurg Psychiatry, 2015, 86(2):135-143.
[58] AARSLAND D, BATZU L, HALLIDAY G M, et al.Parkinson disease-associated cognitive impairment[J]. Nat Rev Dis Primers, 2021, 7(1):47.
[59] DAUWAN M, BEGEMANN M J H, SLOT M I E, et al.Physical exercise improves quality of life, depressive symptoms, and cognition across chronic brain disorders: a transdiagnostic systematic review and meta-analysis of randomized controlled trials[J]. J Neurol, 2021, 268(4):1222-1246.
[60] OPHEY A, GIEHL K, REHBERG S, et al.Effects of working memory training in patients with Parkinson’s disease without cognitive impairment: a randomized controlled trial[J]. Parkinsonism Relat Disord, 2020, 72:13-22.
[61] MAGGIO M G, DE COLA M C, LATELLA D, et al.What about the role of virtual reality in Parkinson disease’s cognitive rehabilitation? preliminary findings from a randomized clinical trial[J]. J Geriatr Psychiatry Neurol, 2018, 31(6):312-318.
[62] CRISPO J A, WILLIS A W, THIBAULT D P, et al.Associations between anticholinergic burden and adverse health outcomes in Parkinson disease[J]. PLoS One, 2016, 11(3):e0150621.
[63] EHRT U, BROICH K, LARSEN J P, et al.Use of drugs with anticholinergic effect and impact on cognition in Parkinson’s disease: a cohort study[J]. J Neurol Neurosurg Psychiatry, 2010, 81(2):160-165.
[64] MAGGI G, TROJANO L, BARONE P, et al.Sleep disorders and cognitive dysfunctions in Parkinson’s disease: a meta-analytic study[J]. Neuropsychol Rev, 2021, 31(4):643-682.